Literature DB >> 25254624

Novel approaches to combat bacterial biofilms.

Christophe Beloin1, Stéphane Renard2, Jean-Marc Ghigo1, David Lebeaux3.   

Abstract

Biofilms formed by pathogenic bacteria and fungi are associated with a wide range of diseases, from device-related infections (such as catheters or prosthetic joints) to chronic infections occurring on native tissues (such as lung infections in cystic fibrosis patients). Biofilms are therefore responsible for an important medical and economic burden. Currently used antibiotics have mostly been developed to target exponentially growing microorganisms and are poorly effective against biofilms. In particular, even high concentrations of bactericidal antibiotics are inactive against a subset of persistent biofilm bacteria, which can cause infection recurrence despite prolonged treatments. While the search for a magic bullet antibiotic effective against both planktonic and biofilm bacteria is still active, alternative preventive and curative approaches are currently being developed either limiting adhesion or biofilm formation or targeting biofilm tolerance by killing persister bacteria. Most of these approaches are adjunctive using new molecules in combination with antibiotics. This review presents promising approaches or strategies that could improve our ability to prevent or eradicate bacterial biofilms in medical settings.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25254624     DOI: 10.1016/j.coph.2014.09.005

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  38 in total

1.  Targeting Enterococcus faecalis biofilms with phage therapy.

Authors:  Leron Khalifa; Yair Brosh; Daniel Gelman; Shunit Coppenhagen-Glazer; Shaul Beyth; Ronit Poradosu-Cohen; Yok-Ai Que; Nurit Beyth; Ronen Hazan
Journal:  Appl Environ Microbiol       Date:  2015-02-06       Impact factor: 4.792

Review 2.  Control of Biofilm Formation: Antibiotics and Beyond.

Authors:  Ammar Algburi; Nicole Comito; Dimitri Kashtanov; Leon M T Dicks; Michael L Chikindas
Journal:  Appl Environ Microbiol       Date:  2017-01-17       Impact factor: 4.792

3.  Discovery and Optimization of nTZDpa as an Antibiotic Effective Against Bacterial Persisters.

Authors:  Wooseong Kim; Andrew D Steele; Wenpeng Zhu; Erika E Csatary; Nico Fricke; Madeline M Dekarske; Elamparithi Jayamani; Wen Pan; Bumsup Kwon; Isabelle F Sinitsa; Jake L Rosen; Annie L Conery; Beth Burgwyn Fuchs; Petia M Vlahovska; Frederick M Ausubel; Huajian Gao; William M Wuest; Eleftherios Mylonakis
Journal:  ACS Infect Dis       Date:  2018-08-28       Impact factor: 5.084

4.  Understanding biofilm formation in intravascular device-related infections.

Authors:  Christophe Beloin; Nuria Fernández-Hidalgo; David Lebeaux
Journal:  Intensive Care Med       Date:  2016-08-06       Impact factor: 17.440

5.  Beyond Antibiotics: New Therapeutic Approaches for Bacterial Infections.

Authors:  Alan R Hauser; Joan Mecsas; Donald T Moir
Journal:  Clin Infect Dis       Date:  2016-03-29       Impact factor: 9.079

6.  Endless Resistance. Endless Antibiotics?

Authors:  Jed F Fisher; Shahriar Mobashery
Journal:  Medchemcomm       Date:  2015-11-03       Impact factor: 3.597

7.  Not so simple, not so subtle: the interspecies competition between Bacillus simplex and Bacillus subtilis and its impact on the evolution of biofilms.

Authors:  Gili Rosenberg; Nitai Steinberg; Yaara Oppenheimer-Shaanan; Tsvia Olender; Shany Doron; Julius Ben-Ari; Alexandra Sirota-Madi; Zohar Bloom-Ackermann; Ilana Kolodkin-Gal
Journal:  NPJ Biofilms Microbiomes       Date:  2016-01-27       Impact factor: 7.290

8.  Silver oxynitrate, an unexplored silver compound with antimicrobial and antibiofilm activity.

Authors:  Joe A Lemire; Lindsay Kalan; Alexandru Bradu; Raymond J Turner
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

9.  A Novel RNase 3/ECP Peptide for Pseudomonas aeruginosa Biofilm Eradication That Combines Antimicrobial, Lipopolysaccharide Binding, and Cell-Agglutinating Activities.

Authors:  David Pulido; Guillem Prats-Ejarque; Clara Villalba; Marcel Albacar; Juan J González-López; Marc Torrent; Mohammed Moussaoui; Ester Boix
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

10.  Disruption of Membrane by Colistin Kills Uropathogenic Escherichia coli Persisters and Enhances Killing of Other Antibiotics.

Authors:  Peng Cui; Hongxia Niu; Wanliang Shi; Shuo Zhang; Hao Zhang; Joseph Margolick; Wenhong Zhang; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.